Immune Globulin Articles
A recent study conducted in Japan showed significant early post-administration improvements in sepsis patients who were given a single-dose administration of intravenous immune globulin (IVIG).
Low-dose intravenous immune globulin added to a course of corticosteroids has been found to be superior to corticosteroid therapy alone in resolving toxic epidermal necrolysis and reducing associated mortality risk.
Investigators concluded that IVIG may be an effective and safe treatment for DM with isolated skin involvement.
The Centers for Disease Control and Prevention has updated its recommendations for the use of VariZIG.
The U.S. Food and Drug Administration has approved a 10 g (50mL) vial size for Hizentra, immune globulin subcutaneous (human).
The U.S. Food and Drug Administration has instructed manufacturers to add information to the current boxed warning in the labeling of all intravenous immune globulin (IVIG) products, and add a similar standardized boxed warning for all subcutaneous and intramuscular IG products.
With the objective of evaluating the safety and tolerability of intravenous immune globulin (IVIG) as a treatment for neuromyelitis optica (NMO), a team of Spanish investigators administered IVIG (0.7 g/kg body weight for three days) every two months to eight patients meeting Wingerchuk’s revised diagnostic criteria for the disorder.
Results from a new study in patients with early Alzheimer’s disease showed a short course of intravenous immune globulin slows the disease’s progression.
A meta-analysis showed IVIG was as effective as plasma exchange in reducing Guillain Barré syndrome disability scores, with no significant difference in adverse events.
A multinational team of investigators exposed cultured neurons with intravenous immunoglobulin (IVIG) to evaluate its effect on downstream signaling pathways involved in neuronal cell death.
Recent studies suggest that the divergent outcomes in Alzheimer’s disease clinical studies of intravenous immune globulin (IVIG) may be due to differences in temporal administration and administered dosages.
An investigational 10% liquid intravenous immunoglobulin product currently under U.S. regulatory review for marketing approval appears to be safe and effective for prophylactic treatment of patients with primary immunodeficiency disorders.